Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.
Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Head Neck. 2022 Feb;44(2):431-442. doi: 10.1002/hed.26941. Epub 2021 Nov 26.
Compared to conventional intensity-modulated photon radiation therapy (IMRT), intensity-modulated proton radiation therapy (IMPT) has potential to reduce irradiation-induced late toxicities while maintaining excellent tumor control in patients with nasopharyngeal carcinoma (NPC). However, the relevant cost-effectiveness remains controversial.
A Markov decision tree analysis was performed under the assumption that IMPT offered normal tissue complication probability reduction (NTCP reduction) in long-term dysphagia, xerostomia, and hearing loss, compared to IMRT. Base-case evaluation was performed on T2N2M0 NPC of median age (43 years old). A Chinese societal willingness-to-pay threshold (33558 US dollars [$])/quality-adjusted life-year [QALY]) was adopted.
For patients at median age and having NTCP reduction of 10%, 20%, 30%, 40%, 50%, and 60%, their incremental cost-effectiveness ratios were $102684.0/QALY, $43161.2/QALY, $24134.7/QALY, $13991.6/QALY, $8259.8/QALY, and $4436.1/QALY, respectively; IMPT should provide an NTCP reduction of ≥24% to be considered cost-effective.
IMPT has potential to be cost-effective for average Chinese NPC patients and should be validated clinically.
与传统调强光子放射治疗(IMRT)相比,调强质子放射治疗(IMPT)有可能在保持鼻咽癌(NPC)患者优异肿瘤控制的同时,降低放疗引起的迟发性毒性。然而,其相关成本效益仍存在争议。
假设与 IMRT 相比,IMPT 可降低长期吞咽困难、口干和听力损失的正常组织并发症概率(NTCP 降低),我们进行了马尔可夫决策树分析。基础情况评估基于 T2N2M0 期 NPC 患者的中位年龄(43 岁)。采用中国社会意愿支付阈值(33558 美元[美元] / 质量调整生命年[QALY])。
对于中位年龄患者和 NTCP 降低 10%、20%、30%、40%、50%和 60%的患者,增量成本效益比分别为 102684.0 美元/QALY、43161.2 美元/QALY、24134.7 美元/QALY、13991.6 美元/QALY、8259.8 美元/QALY 和 4436.1 美元/QALY;IMPT 应提供 ≥24%的 NTCP 降低,才能被认为具有成本效益。
对于普通中国 NPC 患者,IMPT 具有潜在的成本效益,应在临床上进行验证。